<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302079</url>
  </required_header>
  <id_info>
    <org_study_id>8232-CL-3001</org_study_id>
    <nct_id>NCT02302079</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)</brief_title>
  <acronym>VIDI</acronym>
  <official_title>A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with
      diabetic macular edema (DME). This study will evaluate the percent change from baseline in
      excess central subfield thickness (CST) in the study eye as assessed by spectral
      domain-optical coherence Tomography (SD-OCT) for ASP8232 monotherapy at Month 3.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Actual">August 12, 2016</completion_date>
  <primary_completion_date type="Actual">August 12, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT) at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in CST in the study eye as assessed by SD-OCT at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) score in the study eye at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change from baseline in excess CST in the study eye as assessed by SD-OCT at Months 1 and 2</measure>
    <time_frame>Baseline and Months 1, 2</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>ASP8232 + sham intravitreal (IVT) injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP8232 + ranibizumab intravitreal (IVT) injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + ranibizumab intravitreal (IVT) injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP8232</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>ASP8232 + ranibizumab intravitreal (IVT) injections</arm_group_label>
    <arm_group_label>ASP8232 + sham intravitreal (IVT) injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>intravitreal (IVT) injection</description>
    <arm_group_label>ASP8232 + ranibizumab intravitreal (IVT) injections</arm_group_label>
    <arm_group_label>Placebo + ranibizumab intravitreal (IVT) injections</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Placebo + ranibizumab intravitreal (IVT) injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham intravitreal (IVT) injection</intervention_name>
    <description>intravitreal (IVT) injection</description>
    <arm_group_label>ASP8232 + sham intravitreal (IVT) injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a documented diagnosis of type 1 or type 2 diabetes mellitus and a
             glycosylated hemoglobin A1c (HbA1c) of ≤ 12.0% at Screening

          -  Subject has definite retinal thickening due to diffuse diabetic macular edema (DME)
             involving the central macula based on evaluating investigator's clinical evaluation
             and demonstrated by spectral domain-optical coherence tomography (SD-OCT)

          -  Subject has central subfield thickness (CST) of at least 375 μm by SD-OCT with
             presence of intraretinal and/or subretinal fluid at screening visit and at the
             randomization visit

          -  Subject has early treatment diabetic retinopathy study (ETDRS) best corrected visual
             acuity (BCVA) letter score ≤ 73 (Snellen 20/40) and ≥ 24 (Snellen 20/320) at screening
             visit

        Exclusion Criteria:

          -  Subject's study eye has macular edema considered to be due to a cause other than DME

          -  Subject's study eye has a decrease in BCVA due to causes other than DME that is likely
             to be decreasing BCVA by 3 lines or more

          -  Subject's study eye has significant macular ischemia as shown on angiography

          -  Subject's study eye has any other ocular disease that may cause substantial reduction
             in BCVA

          -  Subject has active peri-ocular or ocular infection

          -  Subject's study eye has a history of non-infectious uveitis

          -  Subject's study eye has high myopia (-8 diopter or more correction)

          -  Subject's study eye has a history of prior pars plana vitrectomy

          -  Subject's study eye has a history of any ocular surgery within 3 months prior to Day 1

          -  Subject's study eye has a history of YAG capsulotomy within 3 months prior to Day 1

          -  Subject's study eye has a history of panretinal scatter photocoagulation (PRP) or
             focal laser within 3 months prior to Day 1 or anticipated need for PRP during the
             course of the study through the Week 12 visit

          -  Subject's study eye has a history of prior IVT, subtenon, or periocular, non-sustained
             release, steroid therapy within 3 months prior to Day 1

          -  Subject's study eye has a history of intravitreal sustained release dexamethasone
             therapy within 6 months prior to Day 1.

          -  Subject's study eye has a history of intravitreal sustained release fluocinolone
             within 3 years prior to Day 1.

          -  Subject's study eye has a history of prior treatment for DME with IVT anti-vascular
             endothelial growth factor (VEGF) treatment within 8 weeks prior to Day 1

          -  Subject has a history of prior treatment with any other (than previously listed)
             approved treatment which is not labeled for DME within 1 year prior to Day 1

          -  Subject's study eye has high-risk proliferative diabetic retinopathy (PDR)

          -  Subject has uncontrolled glaucoma

          -  Subject has media clarity, papillary constriction (i.e., senile miosis), or subject
             lacks cooperation that would interfere with any study procedures, evaluations or
             interpretation of data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Lead</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10021</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10025</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10006</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10004</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10007</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10011</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10031</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10029</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10016</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10005</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10036</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10002</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10001</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>985540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10027</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10012</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10010</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10015</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10013</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10030</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10009</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240-1502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10017</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <disposition_first_submitted>August 1, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 1, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2017</disposition_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP8232</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

